Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
09/09/2026 06:34
BRIEF-Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses Sept 9 (Reuters) - EVOTEC SE EVTG.DE:
INITIATES PHASE 1 TRIAL FOR JST-018 ANTIBODIES TARGETING ORTHOPOXVIRUSES
JST-018 DEVELOPED UNDER U.S. DEPARTMENT OF WAR ACCELERATED ANTIBODIES PROGRAM
CONTRACTS WITH U.S. DEPARTMENT OF WAR HAVE POTENTIAL VALUE UP TO $123.90 MILLION
Source text: ID:nEQ6fVjpla
Further company coverage: EVTG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases